Biomolecules (Jul 2020)

Precision Medicine for Lysosomal Disorders

  • Filippo Pinto e Vairo,
  • Diana Rojas Málaga,
  • Francyne Kubaski,
  • Carolina Fischinger Moura de Souza,
  • Fabiano de Oliveira Poswar,
  • Guilherme Baldo,
  • Roberto Giugliani

DOI
https://doi.org/10.3390/biom10081110
Journal volume & issue
Vol. 10, no. 8
p. 1110

Abstract

Read online

Precision medicine (PM) is an emerging approach for disease treatment and prevention that accounts for the individual variability in the genes, environment, and lifestyle of each person. Lysosomal diseases (LDs) are a group of genetic metabolic disorders that include approximately 70 monogenic conditions caused by a defect in lysosomal function. LDs may result from primary lysosomal enzyme deficiencies or impairments in membrane-associated proteins, lysosomal enzyme activators, or modifiers that affect lysosomal function. LDs are heterogeneous disorders, and the phenotype of the affected individual depends on the type of substrate and where it accumulates, which may be impacted by the type of genetic change and residual enzymatic activity. LDs are individually rare, with a combined incidence of approximately 1:4000 individuals. Specific therapies are already available for several LDs, and many more are in development. Early identification may enable disease course prediction and a specific intervention, which is very important for clinical outcome. Driven by advances in omics technology, PM aims to provide the most appropriate management for each patient based on the disease susceptibility or treatment response predictions for specific subgroups. In this review, we focused on the emerging diagnostic technologies that may help to optimize the management of each LD patient and the therapeutic options available, as well as in clinical developments that enable customized approaches to be selected for each subject, according to the principles of PM.

Keywords